Cell–cell interactions, drug‐target expression analyses in malignant cells after radiation, and multiplex immunofluorescence of tumor tissue identified interleukin‐1 receptor type I (IL1R1) as a potential therapeutic target. The gene discussed is IL1R1; the disease is neoplasm.